Exact Therapeutics AS (EXTX) - Total Liabilities
Based on the latest financial reports, Exact Therapeutics AS (EXTX) has total liabilities worth Nkr37.65 Million NOK (≈ $3.96 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Exact Therapeutics AS - Total Liabilities Trend (2017–2024)
This chart illustrates how Exact Therapeutics AS's total liabilities have evolved over time, based on quarterly financial data. See Exact Therapeutics AS short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Exact Therapeutics AS Competitors by Total Liabilities
The table below lists competitors of Exact Therapeutics AS ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IMPRENDIROMA S.P.A.
F:Y37
|
Germany | €22.61 Million |
|
Wirtek A/S
CO:WIRTEK
|
Denmark | Dkr19.63 Million |
|
Stonehorse Energy Ltd
AU:SHE
|
Australia | AU$333.78K |
|
East Side Games Group Inc
TO:EAGR
|
Canada | CA$17.63 Million |
|
Nikola Corp
NASDAQ:NKLA
|
USA | $656.80 Million |
|
XiDeLang Holdings Ltd
KLSE:5156
|
Malaysia | RM67.01 Million |
|
Multi-Usage Holdings Bhd
KLSE:9539
|
Malaysia | RM3.97 Million |
|
SG COMPANY S.P.A.
F:7KZ
|
Germany | €28.49 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Exact Therapeutics AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see EXTX market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.65 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Exact Therapeutics AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Exact Therapeutics AS (2017–2024)
The table below shows the annual total liabilities of Exact Therapeutics AS from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr37.65 Million ≈ $3.96 Million |
+132.15% |
| 2023-12-31 | Nkr16.22 Million ≈ $1.71 Million |
-6.79% |
| 2022-12-31 | Nkr17.40 Million ≈ $1.83 Million |
+46.38% |
| 2021-12-31 | Nkr11.89 Million ≈ $1.25 Million |
+12.36% |
| 2020-12-31 | Nkr10.58 Million ≈ $1.11 Million |
+7.21% |
| 2019-12-31 | Nkr9.87 Million ≈ $1.04 Million |
+59.89% |
| 2018-12-31 | Nkr6.17 Million ≈ $649.40K |
-47.15% |
| 2017-12-31 | Nkr11.68 Million ≈ $1.23 Million |
-- |
About Exact Therapeutics AS
EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. … Read more